In the GLP-1 segment, Gland launched Liraglutide in Q4 FY25 and is scaling production capacity from ~40 million to 140 million units, while exploring opportunities beyond GLP-1 therapies
ERK1/2 & VEGFR2 Mechanism Musculoskeletal Scoping Review (PMC, 2025) A 2025 scoping review confirmed BPC-157 activates VEGFR2 and drives nitric oxide synthesis via the Akt-eNOS axis, promoting angiogenesis, fibroblast activity, and neuromuscular stabilisation
GHK-Cu stimulates production of both Type I collagen (structural support) and Type III collagen (tissue flexibility and repair)
"I love my results from Laser Hair Removal...quick and painless!" - Diana Sparks, @iamdianasparks "Im already seeing major results after just one Laser Hair Removal treatment whereas when Ive gone to a different laser center, it took 4 treatments to see any progress!" - Gigi Yablow, @gigiibee "I was super nervous coming in because it was my first session but everyone was so friendly and walked me through everything
Asia Pacific is expected to grow at the fastest CAGR between 2026 and 2035
